A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder

Ki vehet részt

• Men and women age 18-65 years
• Primary diagnosis of OCD
• YBOCS score of at least 21 at baseline (moderate or higher severity)
• Ability to understand and sign the consent form

Ki nem vehet részt

• Use of any new psychotropic medication within 3 months of study entry (stable doses of psychotropics will be allowed)
• Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination
• History of psychosis or bipolar disorder based on DSM-5 criteria
• Alcohol/substance use disorder and/or illegal substance use based on urine toxicology
• Major cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent
• Current pregnancy or lactation, or inadequate contraception in women of childbearing potential
• Subjects considered an immediate suicide risk based on the Columbia Suicide Severity rating Scale (C-SSRS) (www.cssrs.columbia.edu/docs)
• Initiation of psychological interventions within 3 months of screening (those who are continuing with CBT will be included)
• Abnormal liver function tests at baseline
• MADRS >30 at baseline